Genomics & Omics Analysis - software & AI news

Daily news on software, AI, and companies shaping genomics & omics analysis.

Showing 76 results
Genomic sequencing machine in a laboratory

Jul 29, 2026

Precision oncology move to put Amaravati on India's genomics map

Andhra Pradesh is making strides in precision oncology with the establishment of an Integrated Genomics Solutions Center in Amaravati, a collaboration between the state government and AstraZeneca India. This initiative marks a significant advancement in cancer care, aiming to integrate genomics and artificial intelligence for personalized treatment.The Memorandum of Understanding (MoU) was signed in the presence of Chief Minister N Chandrababu Naidu, emphasizing the project's focus on lung and b
Probiotic capsule and gut microbiome illustration

Jul 28, 2026

From Queensland to Silicon Valley: Australian student founders join startup elite with AI driven biotech venture

Two Australian university students, Anis Mihrshahi and Leon Mojarrabi, have joined the prestigious Y Combinator startup accelerator with their biotech venture, GutGutGoose. This achievement highlights a growing trend of student-led innovation in the life sciences sector, particularly in the realm of personalized healthcare.GutGutGoose aims to revolutionize the probiotic market by leveraging artificial intelligence to develop customized probiotics tailored to individual gut microbiomes. The found
A minimalist representation of DNA and a laboratory flask on a dark background.

Jul 28, 2026

A.P. inks pact with AstraZeneca to set up Genomic Solutions Centre in Amaravati

Andhra Pradesh has officially partnered with AstraZeneca India to create an Integrated Genomic Solutions Centre in Amaravati, a significant advancement in precision cancer care. This initiative aims to establish India's first comprehensive research and treatment ecosystem focused on precision oncology, utilizing cutting-edge genomic technologies for personalized cancer diagnosis and treatment.The Memorandum of Understanding (MoU) was signed in the presence of Chief Minister N. Chandrababu Naidu,
A minimalist representation of a single cell and gene strands in a dark palette.

Jul 28, 2026

Novogene Europe Adds Single-Cell Sequencing at Cambridge Omics Centre

Novogene Europe has enhanced its single-cell RNA sequencing capabilities at the Cambridge Omics Centre, providing advanced sequencing services to researchers in the UK.This development leverages Novogene's established expertise in single-cell technologies, integrating specialized project support, sequencing infrastructure, and bioinformatics analysis. The aim is to facilitate deeper biological insights from complex samples, responding to the increasing demand for accessible single-cell transcrip
Illustration of a single cell with RNA strands

Jul 27, 2026

Novogene Europe Adds Single-Cell Sequencing at Cambridge Omics Centre

Novogene Europe has enhanced its single-cell RNA sequencing capabilities at the Cambridge Omics Centre, making advanced sequencing workflows more accessible to researchers in the UK.This expansion leverages Novogene's expertise in single-cell analysis, integrating specialized project support, sequencing technologies, and bioinformatics to facilitate deeper biological insights from complex samples. The service addresses the increasing demand for single-cell transcriptomics, enabling researchers t
A minimalist representation of a base editor and DNA strand in a dark color scheme.

Jul 25, 2026

AlphaFold AI redesigns gene-editing proteins to enhance safety, and biotech investors should pay attention

A new AI framework named ContactSeek, built on the advancements of AlphaFold3, is set to revolutionize gene-editing technologies by enhancing their safety and precision. This innovation is particularly significant for biotech investors and stakeholders in the field of gene therapy.ContactSeek addresses a critical challenge in gene editing: the risk of unintended DNA cuts. By utilizing AlphaFold3's structural predictions, the framework allows researchers to redesign base editors—molecular tools t
Petri dish with cultured human cells in a dim laboratory setting

Jul 22, 2026

The biotech bi-weekly: multiomics, human cell-based research, next-gen cell recovery and biomarker development

This week in biotech highlights significant advancements in multiomics, human cell research, and innovative production methods involving microbes.Novogene Europe has bolstered its multiomics capabilities with the launch of an Untargeted Metabolomics Service at its Cambridge Omics Centre. This service aims to enhance the understanding of molecular interactions by integrating metabolomic data with genomics and other life sciences, providing researchers with deeper insights into biological function
A minimalist illustration of a DNA strand representing genomic testing.

Jul 22, 2026

Tempus AI to Acquire Cancer Diagnostics Firm Personalis for approximately $1.5 Billion, Targeting MRD Market Leadership

Tempus AI is set to acquire Personalis, a cancer genomics testing firm, in a strategic move valued at approximately $1.5 billion. This acquisition aims to enhance Tempus AI's capabilities in the rapidly expanding minimal residual disease (MRD) testing market, projected to be worth $20 billion.Under the terms of the agreement, Tempus AI will purchase all outstanding shares of Personalis at $16.25 each, reflecting a premium over recent stock prices. The deal is primarily an all-stock transaction,
A genome sequencing sample in a clinical setting with an MRI machine in the background.

Jul 12, 2026

Whole Genome Interpretation Services

Simplify Genomics and SimonMed have joined forces to enhance preventive healthcare through a novel integration of whole genome interpretation and advanced MRI technology.This collaboration leverages Simplify Genomics' expertise in whole genome analysis, supported by its CAP/CLIA-certified platform that has processed over 50,000 genomes. This platform not only identifies numerous disease associations but also provides pharmacogenomic insights. On the other hand, SimonMed contributes its extensive
A minimalist representation of a test tube with an aptamer inside, symbolizing molecular diagnostics.

Jul 12, 2026

En Carta Diagnostics secures 5 million euros for home testi

En Carta Diagnostics has successfully raised 5 million euros to enhance its molecular testing capabilities for Lyme disease and sexually transmitted infections (STIs), focusing on both the US and European markets.The Paris-based startup secured 3 million euros in equity funding led by Blue Forest Ventures, with contributions from Ring Capital and others, alongside an additional 2 million euros in non-dilutive funding from Bpifrance. Founded in 2022, En Carta aims to develop home-based diagnostic
A stack of banknotes on a lab countertop with equipment in the background

Jul 9, 2026

Alchemab extends Series A with £25m from British Business Bank

Alchemab has successfully secured an additional £25 million in funding from the British Business Bank, marking a significant milestone as it represents the largest direct investment in life sciences by the bank to date. This investment aligns with the UK’s strategic efforts to retain high-growth biotech firms within its borders.Previously, Alchemab raised £60 million in its initial Series A round in 2021, which was intended to propel its initiatives in neurodegeneration and cancer therapies. The
Silhouette of a computational biologist with a magnifying glass against a solid background.

Jul 8, 2026

Lantern Pharma Launches ZetaOmics, an AI-Powered Computational Biology Platform

Lantern Pharma has unveiled ZetaOmics, an innovative AI-driven computational biology platform designed to enhance cancer research through advanced bioinformatics.This new module, part of the company's multi-agentic AI co-scientist platform withZeta.ai, features an autonomous agent termed the “Computational Biologist.” This agent is engineered to conduct comprehensive bioinformatics and multi-omic analyses across diverse cancer types. Initially accessible via an early-access program for select co